Flowonix Medical, Inc. and SWK Holdings Corporation announced that they have closed an approximate $33 million financing. The financing includes $10 million in debt facility from SWK Holdings and the completion of an approximate $23 Series B round led by Farallon Capital Management with participation of several additional new investors. The Company expects to use the proceeds from this financing to replace prior venture debt, plus fund its business plan, including: development of next generation products, expansion of its production line, and continued collaborations with pharmaceutical companies. This will enable Flowonix to not only expand into current markets, but also to begin applying targeted drug delivery into new disease states with larger medical markets.